Rossari Biotech Posts ₹1,129.8 Crore Revenue in H1 FY26

Rossari Biotech Limited has announced strong financial results for the quarter and half-year ended September 30, 2025. The company posted double-digit revenue growth across all business segments, supported by robust export performance and strategic capacity expansions.

Despite pricing pressures, profitability remained stable, reflecting operational efficiency. Management remains optimistic about future growth, especially in international markets.

Q2 FY26 Financial Performance

Rossari Biotech recorded operating revenue of ₹586.1 crore in Q2 FY26, an 18% year-on-year increase from ₹498.4 crore in Q2 FY25. EBITDA rose 9% YoY to ₹71.9 crore, with an EBITDA margin of 12.3%.

Profit after tax (PAT) grew 5% YoY to ₹36.9 crore, and diluted earnings per share (EPS) stood at ₹6.7 for the quarter. The company attributed the growth to strong volumes across its diversified product portfolio.

H1 FY26 Performance Overview

For the half-year ended September 2025, Rossari reported revenue of ₹1,129.8 crore, up 14% YoY. EBITDA increased 7% to ₹139.7 crore, maintaining a margin of 12.4%.

PAT remained steady at ₹70.5 crore compared to ₹70.2 crore in H1 FY25, with EPS at ₹12.7. The company’s consistent performance reflects its ability to manage costs while expanding its market presence.

Segment and Export Growth

Rossari achieved notable growth across its three key verticals in Q2 FY26:

• Home, Personal & Performance Chemicals (HPPC): +16% YoY
• Textile Specialty Chemicals (TSC): +21% YoY
• Animal Health & Nutrition (AHN): +29% YoY

Exports rose 36% YoY in Q2 and 27% in H1, contributing nearly 28% of total sales. This growth was driven by deeper customer engagement and entry into new international markets.

Key Strategic Developments

The company commissioned an additional 20,000 MTPA capacity at its Dahej facility, raising total installed capacity to 1,52,500 MTPA. At Unitop, Phase 1 of a 30,000 MTPA ethoxylation project added 15,000 MTPA capacity, with Phase 2 expected in Q3 FY26.

Rossari also approved up to USD 8 million investment in its Saudi Arabia subsidiary, Rossari International Limited Company (RILC), to support global expansion and market development.

Read More: Government Unveils Biomanufacturing Hubs

Conclusion

Rossari Biotech’s Q2 and H1 FY26 results highlight its resilience and strategic focus in a competitive market. Strong volume growth, export expansion, and capacity additions have positioned the company for sustained performance.

Management’s commitment to innovation and global outreach supports its long-term vision. Investors will continue to monitor its progress as it strengthens its presence in the specialty chemicals industry.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.